Could a simple blood test spare thyroid cancer patients from unnecessary radiation?
NCT ID NCT04290663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two approaches for treating intermediate-risk thyroid cancer after surgery. One group gets radioactive iodine as a standard precaution. The other group only gets it if a blood test and scan show signs of remaining cancer. The goal is to see if the selective approach works just as well while avoiding unnecessary treatment and side effects. About 368 patients will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radioactive iodine (I-131)
- What this could lead to
- If successful, this could spare many patients from unnecessary radioactive iodine treatment and its side effects, while still controlling the cancer effectively.
- What could go wrong
- This is a phase 3 trial, but it is still ongoing and results are not yet known. The guided approach might miss some cases that need treatment, or the two strategies could prove equally effective, meaning no change in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP Pitié Salpétrière
RECRUITINGParis, France
-
Bergonié
RECRUITINGBordeaux, France
-
CHU Pointe à pitre
NOT_YET_RECRUITINGPointe à Pitre, Guadeloupe, France
-
CHU TOULOUSE, Hôpital Larrey
RECRUITINGToulouse, France
-
CHU Timone
RECRUITINGMarseille, France
-
Centre Antoine Lacassagne -
RECRUITINGNice, France
-
Centre Francois Baclesse
RECRUITINGCaen, France
-
Centre Georges-François Leclerc
RECRUITINGDijon, France
-
Centre Henri Becquerel
RECRUITINGRouen, France
-
Centre Hospitalier Métropôle Savoie
RECRUITINGChambéry, France
-
Centre Jean Godinot
RECRUITINGReims, France
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, France
-
Centre Léon Bérard
RECRUITINGLyon, France
-
Centre Paul Strauss
RECRUITINGStrasbourg, France
-
Chru Lille
RECRUITINGLille, France
-
Chu Angers
RECRUITINGAngers, France
-
Chu Brest
RECRUITINGBrest, France
-
Chu Grenoble
RECRUITINGGrenoble, France
-
Chu Martinique
RECRUITINGFort de France, France
-
Chu Nancy
RECRUITINGNancy, France
-
Chu Nantes
RECRUITINGNantes, France
-
Chu Nimes
RECRUITINGNîmes, France
-
Hospices Civils de Lyon
RECRUITINGLyon, France
-
Hôpital saint-André
RECRUITINGBordeaux, France
-
IUCT Oncopole
RECRUITINGToulouse, France
-
Institu de Cancérologie de l'Ouest - Site Angers
RECRUITINGAngers, France
-
Institu de Cancérologie de l'Ouest - Site St Herblain
RECRUITINGSaint-Herblain, France
-
Institut CURIE, site Réné Huguenin
RECRUITINGSaint-Cloud, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?